TABLE 3.
Extrapolated nationwide respiratory syncytial virus (RSV) hospitalization costs in adults in the United States
| Age group (years) | Mean cost (2020 $) per hospitalization and CI95 | Incidence rate per 100,000 persons and CI95 a , 4 | US population estimates as of 2019 19 | Total and CI95 b |
|---|---|---|---|---|
| 18–49 | $11,124 [$6522–$17,386] | 9.8 [7.8–12.3] | 138,216,422 | $150,676,909 [$42,505,143–$258,848,674] |
| 50–64 | $7384 [$5743–$9534] | 57.3 [49.2–66.9] | 62,925,688 | $266,240,600 [$156,774,727–$375,706,472] |
| >65 | $8241 [$6957–$9758] | 167 [150.9–184.7] | 54,058,263 | $743,975,223 [$542,253,355–$945,697,091] |
| Grand total | $1,160,925,844 [$907,222,838–$1,414,628,849] | |||
a
Standard errors were estimated by using the delta method for which the correlation measurement was assumed to be 1.
b
Limited to 2017–2018 and 2018–2019 RSV season data to be consistent with the current study.